Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pevifoscorvir (Aligos Therapeutics)
- Development stage
- Unknown
- Lead developer
- Aligos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pevifoscorvir (formerly ALG-000184) is an orally bioavailable, small molecule capsid assembly modulator (CAM) of the class-E (empty) phenotype, developed by Aligos Therapeutics for the treatment of chronic hepatitis B virus (HBV) infection. It is a prodrug of the active metabolite ALG-001075. Pevifoscorvir works by binding to the HBV core protein (HBcAg), disrupting capsid assembly, preventing pregenomic RNA (pgRNA) encapsidation, and blocking the establishment and replenishment of covalently closed circular DNA (cccDNA). In clinical trials, pevifoscorvir has demonstrated potent, sustained reductions in HBV DNA, RNA, and viral antigens (HBsAg, HBeAg, and HBcrAg). In 2026, Aligos entered into an exclusive licensing agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir in Greater China.
- Other names
- PEVYpevifoscorvir sodiumpevifoscovirpevifoscovir sodium
02
Targets
HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on pevifoscorvir (Aligos Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pevifoscorvir (Aligos Therapeutics).